Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for EOLS

Show aggregate EOLS holdings

News associated with EOLS

BTIG Research Reiterates Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $18.00 target price on the stock. BTIG Research’s price objective would indicate a potential upside of 143.57% from the company’s current price. […] - 2025-09-10 02:40:50

Evolus (NASDAQ:EOLS) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Evolus (NASDAQ:EOLS – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. A number of other brokerages have also recently issued reports on EOLS. HC Wainwright reduced their price objective on Evolus from $27.00 to $20.00 and set a “buy” […] - 2025-08-12 03:11:00

Evolus (NASDAQ:EOLS) Hits New 1-Year Low Following Analyst Downgrade

Shares of Evolus, Inc. (NASDAQ:EOLS – Get Free Report) hit a new 52-week low during mid-day trading on Thursday after BTIG Research lowered their price target on the stock from $21.00 to $18.00. BTIG Research currently has a buy rating on the stock. Evolus traded as low as $5.85 and last traded at $6.37, with […] - 2025-08-07 02:24:59

Y Intercept Hong Kong Ltd Invests $449,000 in Evolus, Inc. (NASDAQ:EOLS)

Y Intercept Hong Kong Ltd purchased a new position in Evolus, Inc. (NASDAQ:EOLS – Free Report) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 37,361 shares of the company’s stock, valued at approximately $449,000. Other large investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a […] - 2025-07-29 05:16:59

Evolus (NASDAQ:EOLS) Shares Down 5.5% on Insider Selling

Evolus, Inc. (NASDAQ:EOLS – Get Free Report) shares dropped 5.5% on Tuesday following insider selling activity. The company traded as low as $9.31 and last traded at $9.42. Approximately 110,433 shares traded hands during trading, a decline of 88% from the average daily volume of 938,410 shares. The stock had previously closed at $9.96. Specifically, […] - 2025-06-18 02:10:53

Evolus (NASDAQ:EOLS) Shares Gap Up After Insider Buying Activity

Evolus, Inc. (NASDAQ:EOLS – Get Free Report) shares gapped up before the market opened on Wednesday following insider buying activity. The stock had previously closed at $9.87, but opened at $10.17. Evolus shares last traded at $10.38, with a volume of 256,876 shares. Specifically, Director Albert G. White III bought 20,000 shares of the company’s […] - 2025-06-12 02:15:00

Man Group plc Purchases Shares of 10,931 Evolus, Inc. (NASDAQ:EOLS)

Man Group plc purchased a new stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,931 shares of the company’s stock, valued at approximately $121,000. A number of other hedge funds also recently bought and sold shares […] - 2025-05-29 05:40:57

Nuveen Asset Management LLC Has $8.50 Million Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Nuveen Asset Management LLC lowered its stake in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 14.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 769,576 shares of the company’s stock after selling 127,530 shares during the quarter. Nuveen Asset Management LLC’s holdings in Evolus were worth $8,496,000 as of its most […] - 2025-05-29 04:56:56

BNP Paribas Financial Markets Has $400,000 Position in Evolus, Inc. (NASDAQ:EOLS)

BNP Paribas Financial Markets cut its stake in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 42.3% during the 4th quarter, Holdings Channel reports. The fund owned 36,213 shares of the company’s stock after selling 26,535 shares during the period. BNP Paribas Financial Markets’ holdings in Evolus were worth $400,000 as of its most […] - 2025-05-26 04:24:47

Price T Rowe Associates Inc. MD Buys 6,332 Shares of Evolus, Inc. (NASDAQ:EOLS)

Price T Rowe Associates Inc. MD increased its stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 13.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 52,593 shares of the company’s stock after acquiring an additional 6,332 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Evolus were worth […] - 2025-05-13 04:32:48

Schonfeld Strategic Advisors LLC Increases Position in Evolus, Inc. (NASDAQ:EOLS)

Schonfeld Strategic Advisors LLC lifted its position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 62.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 34,700 shares of the company’s stock after buying an additional 13,363 shares during the period. Schonfeld Strategic Advisors LLC’s holdings in […] - 2025-05-12 05:42:54

Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Invesco Ltd.

Invesco Ltd. reduced its position in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 81.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 18,326 shares of the company’s stock after selling 83,072 shares during the quarter. Invesco Ltd.’s holdings in Evolus were worth $202,000 at the end of the most recent quarter. Other institutional investors […] - 2025-05-05 04:26:46

Thursday's ETF Movers: IHE, IHF

In trading on Thursday, the iShares U.S. Pharmaceuticals ETF is outperforming other ETFs, up about 4.6% on the day. Components of that ETF showing particular strength include shares of Eli Lilly, up about 16.3% and shares of Evolus, up about 5.4% on the day. And underperformin - 2025-04-17 13:05:12

ExodusPoint Capital Management LP Purchases New Position in Evolus, Inc. (NASDAQ:EOLS)

ExodusPoint Capital Management LP acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 13,525 shares of the company’s stock, valued at approximately $149,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes […] - 2025-04-15 04:38:57

KLP Kapitalforvaltning AS Invests $106,000 in Evolus, Inc. (NASDAQ:EOLS)

KLP Kapitalforvaltning AS bought a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,600 shares of the company’s stock, valued at approximately $106,000. Several other large investors have also recently added to or reduced their […] - 2025-04-11 05:14:55

Evolus, Inc. (NASDAQ:EOLS) Position Boosted by Intech Investment Management LLC

Intech Investment Management LLC raised its holdings in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 32.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,674 shares of the company’s stock after acquiring an additional 4,613 shares during the period. […] - 2025-03-27 06:29:02

HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 100.00% from the stock’s current price. Several […] - 2025-03-07 04:50:44

China Universal Asset Management Co. Ltd. Acquires 1,291 Shares of Evolus, Inc. (NASDAQ:EOLS)

China Universal Asset Management Co. Ltd. grew its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 10.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 13,426 shares of the company’s stock after acquiring an additional 1,291 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Evolus were worth $148,000 […] - 2025-02-04 06:53:02

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc EOLS holdings

Date	Number of EOLS Shares Held	Base Market Value of EOLS Shares	Local Market Value of EOLS Shares	Change in EOLS Shares Held	Change in EOLS Base Value	Current Price per EOLS Share Held	Previous Price per EOLS Share Held
2025-09-26 (Friday)	13,341	USD 79,913	USD 79,913
2025-09-25 (Thursday)	13,341	USD 79,779	USD 79,779	0	USD -1,468	USD 5.97999	USD 6.09002
2025-09-24 (Wednesday)	13,341	USD 81,247	USD 81,247
2025-09-17 (Wednesday)	13,255	USD 86,423	USD 86,423	0	USD 0	USD 6.52003	USD 6.52003
2025-09-16 (Tuesday)	13,255	USD 86,423	USD 86,423
2025-09-12 (Friday)	13,169	USD 94,685	USD 94,685
2025-09-11 (Thursday)	13,169	USD 98,899	USD 98,899

Share Trades of EOLS by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-43			7.425*		11.92 Profit of 512 on sale
2025-07-31	BUY	129			8.920*		11.96
2025-06-30	SELL	-86			9.210*		12.30 Profit of 1,058 on sale
2025-06-25	SELL	-43			9.100*		12.37 Profit of 532 on sale
2025-06-20	SELL	-86			9.280*		12.43 Profit of 1,069 on sale
2025-05-23	BUY	43			9.680*		12.88
2025-05-19	SELL	-43			9.900*		12.99 Profit of 559 on sale
2025-05-15	SELL	-129			10.000*		13.04 Profit of 1,683 on sale
2025-05-12	SELL	-43			9.980*		13.12 Profit of 564 on sale
2025-05-09	SELL	-43			9.800*		13.15 Profit of 566 on sale
2025-04-30	SELL	-43			11.400*		13.26 Profit of 570 on sale
2025-04-24	SELL	-86			11.550*		13.33 Profit of 1,147 on sale
2025-04-17	SELL	-43			10.790*		13.47 Profit of 579 on sale
2025-04-15	SELL	-129			10.230*		13.54 Profit of 1,747 on sale
2025-04-14	SELL	-129			10.270*		13.58 Profit of 1,751 on sale
2025-04-09	SELL	-172			10.370*		13.71 Profit of 2,357 on sale
2025-04-07	SELL	-301			10.240*		13.80 Profit of 4,152 on sale
2025-04-04	SELL	-430			10.690*		13.83 Profit of 5,947 on sale
2025-03-31	BUY	43			12.030*		13.89
2025-03-19	SELL	-86			13.470*		14.02 Profit of 1,206 on sale
2025-03-14	SELL	-258			13.200*		14.05 Profit of 3,624 on sale
2025-03-13	SELL	-86			12.960*		14.06 Profit of 1,209 on sale
2025-03-12	SELL	-1,462			13.420*		14.07 Profit of 20,570 on sale
2025-03-07	SELL	-86			13.580*		14.12 Profit of 1,214 on sale
2025-03-06	SELL	-129			13.500*		14.13 Profit of 1,822 on sale
2025-03-03	SELL	-43			14.340*		14.12 Profit of 607 on sale
2025-02-28	BUY	8,327			14.590*		14.11
2025-02-26	SELL	-20			14.320*		14.11 Profit of 282 on sale
2025-02-25	SELL	-60			13.960*		14.11 Profit of 847 on sale
2025-02-18	BUY	100			14.790*		14.06
2025-02-13	BUY	20			15.040*		14.02
2025-02-12	BUY	20			14.260*		14.01
2025-02-11	BUY	60			13.770*		14.02
2025-02-06	BUY	180			13.410*		14.07
2025-01-27	BUY	20			14.760*		14.11
2024-12-30	BUY	100			10.890*		14.29
2024-12-06	BUY	80			12.660*		14.49
2024-12-05	BUY	20			12.690*		14.55
2024-12-04	BUY	100			12.960*		14.61
2024-11-29	BUY	100			13.690*		14.75
2024-11-27	BUY	80			13.800*		14.84
2024-11-26	BUY	20			12.830*		14.93
2024-11-21	BUY	100			13.040*		15.27
2024-11-20	BUY	60			12.630*		15.41
2024-11-18	BUY	240			11.990*		15.82
2024-11-12	BUY	160			12.440*		16.04
2024-11-08	BUY	100			13.680*		16.21
2024-11-07	BUY	300			14.290*		16.36
2024-11-06	BUY	40			16.810*		16.32
2024-10-31	BUY	20			16.320*		16.23

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of EOLS

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer